By Michelle Koidin Jaffee
A team of University of Florida Health neurosurgeons and neurologists recently became the first in the U.S. to implant a newly FDA-approved, technologically advanced deep brain stimulation system designed to more precisely target motorsymptoms of Parkinson’s disease and two other movement disorders.
The team performed the procedure to implant Medtronic’s SenSight™ Directional Lead System in early June, shortly after its approval by the U.S. Food and Drug Administration for use in treating symptoms of Parkinson’s disease, dystonia and essential tremor.
Deep brain stimulation, or DBS, is an established treatment used in some patients to alleviate symptoms such as tremor, slowness and abnormal muscle contractions. In appropriately selected patients with debilitating symptoms despite treatment with medications, the addition of DBS therapy can provide significant symptomatic relief.